The U.S. Food and Drug Administration today approved expanded use of Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate deficiency in adult and pediatric patients who have a confirmed variant in the folate receptor 1 gene (CFD-FOLR1).
FDA News Releases published a clinical update in Research Highlights on 10 Mar 2026. The item focuses on FDA Approves First Treatment for Patients with Cerebral Folate Transport Deficiency. Open the detail page to review the full original feed content.